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Summary Photodynamic therapy is a method for treating cancer using drugs activated by light. A new compound, 5-aminolaevulinic acid
(ALA), is a precursor of the active photosensitizer protoporphyrin IX (PpIX) and has fewer side-effects and much more transient phototoxicity
than previous photosensitizers. Cell survival of ALA-mediated photodynamic therapy was measured in the J82 bladder cancer cell line, along
with its mitomycin C-resistant counterpart J82/MMC. This demonstrated that mitomycin resistance is not cross-resistant to photodynamic
therapy. There was also a suggestion that the mitomycin-resistant cells were more susceptible to photodynamic therapy than the parent cell
line. Photodynamic therapy appeared to enhance the effect of mitomycin C, when mitomycin C was given first. This phenomenon was
apparent for both drug-resistant and drug-sensitive cell lines. This suggests a possible role for combined mitomycin C and photodynamic
therapy in superficial bladder tumours that have recurred despite intravesical cytotoxic drug treatment.
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Photodynamic therapy is a method for the treatment ofcancer that
involves the administration ofphotosensitizer drugs that are pref-
erentially taken up by tumour and activated in the presence oflight
to cause tissue destruction (Dougherty et al, 1988). Transitional
cell carcinoma ofthe bladder is an ideal tumour for this treatment
modality as the usually superficial nature ofthe disease allows for
good light penetration. The available sensitizers, until recently,
have been mixtures of porphyrins such as haematoporphyrin
derivative and Photofrin (Quadralogic Technologies), which have
been approved in Canada for the treatment of superficial bladder
cancers. A problem with first-generation sensitizers is that of
prolonged skin photosensitivity. Phototoxic incidences of20-40%
have been reported during follow-up of patients having received
Photofrin, with a mean duration ofskinphotosensitivity exceeding
6 weeks (Dougherty et al, 1990). Some of these photosensitizers
can also be taken up in significant amounts by detrusor, resulting
in muscle damage and bladder contractures (Harty et al, 1989).
The use of 5-aminolaevulinic acid (ALA) in photodynamic
therapy represents a new strategy in the search for newer and less
toxic photosensitizers. ALA is not itself a photosensitizer, but
induces the synthesis in situ ofapure endogenous porphyrin called
protoporphyrin IX (PpIX). The formation of PpIX forms part of
the haem synthesis pathway and all nucleated cells that use
oxidative metabolism are probably capable of forming this
photosensitizer. However, malignant tissue appears to preferen-
tially accumulate PpIX, forming the basis of photodynamic
therapy in cancer (Battle, 1993; Kennedy and Pottier, 1994).
Unlike first-generation photosensitizers, which need to be injected
systemically, ALA can be administered intravesically with
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minimal systemic toxicity and encouraging early results of ALA-
mediated photodynamic therapy ofthe bladder have recently been
reported (Kriegmair et al, 1996).
Photodynamic therapy works by the generation of singlet
oxygen that results in damage to cell membrane structures,
microvascular ischaemia and tissue necrosis. When ALA is used,
the mitochondria are important targets (Rossi et al, 1996). This is
in contrast to conventional intravesical cytotoxic drugs, such as
mitomycin C, which target DNA and the cell nucleus. The ability
ofmitomycin C to enhance the effect ofphotodynamic therapy has
been established both in vivo (Bass et al, 1994; 1996) and at a
cellular level (Maet al, 1992; 1993). The purpose ofthis study was
to examine the enhanced activity that could be expected with these
two treatment modalities, with particular respect to the possible
effect ofALA-mediated photodynamic therapy with mitomycin C
on a mitomycin-resistant cell line.
MATERIALS AND METHODS
Cell lines
The poorly differentiated human bladder transitional cell carci-
noma cell line, J82, was obtained from the American Type Culture
Collection (Rockville). The cells were maintained as monolayer
cultures in 25-cm2 tissue culture flasks in Dulbecco's modified
Eagle medium (DMEM) (Gibco) supplemented with 10% fetal
calf serum (Gibco) and 1% penicillin and streptomycin (Sigma) at
37°C and 5% carbon dioxide. Cells were subcultured when
confluent using 0.5% trypsin-10% EDTA in phosphate-buffered
saline (PBS). A mitomycin-resistant cell line, J82/MMC, was
derived using methodology previously described (Xu et al, 1994).
Briefly, increasing concentrations of mitomycin C (Kyowa)
starting at 2 ng ml-l were added to the J82 cell culture medium
over a 6-month period. The final concentration of mitomycin
(MMC) used was 19 ng ml-1 and the cells were subcultured at least
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twice before verifying drug resistance by performing cell survival
assays, following exposure to serial dilutions of MMC. The
J82/MMC cells were cultured for a further 2 months in MMC-free
medium without losing their relative MMC resistance. The growth
rates of both cell lines were similar in ordinary cell culture
medium.
Measurement of protoporphyrin IX accumulation
Confluent cell cultures were removed from their flasks by
trypsinization and resuspended in serum-supplemented DMEM to
neutralize the trypsin. The cells were centrifuged at 150 g for
5 min and the pellet resuspended in freshly prepared serum-free
DMEM containing 1 mm ALA to give approximately 1 x 106 cells
per 5 ml of medium. The cell suspensions were placed in 25-cm2
flasks lined with a layer of 2% agar to prevent the cells sticking
down. A paired flask ofcell suspension in serum-free DMEM, but
with no ALA, was also prepared to act as a control. A 0.5-ml
sample of cell suspension was immediately removed from each
of the paired flasks to measure background fluorescence. Cell
suspensions were incubated at 370C in 5% carbon dioxide and
0.5-ml samples removed every 1-1.5 h from both sets offlasks to
measure ALA-induced fluorescence. Flasks were gently shaken at
these times, but otherwise left undisturbed.
Cellular fluorescence was quantitated with a FACScan flow
cytometer (Becton-Dickinson). ALA-induced fluorescence was
excited with an argon laser emitting at 488 nm and emission was
collected by aphotomultiplier tube afterpassing through a 650-nm
longpass filter. Data from 5 x 103 cells were recorded and
processed using the LYSIS II software (Becton-Dickinson). Using
side and forward scatter signals, debris was excluded from the
final data. ALA-induced fluorescence was determined at various
times by subtracting the fluorescence of the control cell suspen-
sions from that of the ALA-incubated cells. The source of
ALA-induced fluorescence was confirmed to be because of accu-
mulation of protoprophyrin IX by checking the absorption and
emission spectra of a sample of ALA-incubated cells with a
standard PpIX solution on a spectrophotometer (Perkin-Elmer).
Photodynamic therapy
Confluent cells growing as a monolayer were trypsinized, resus-
pended in DMEM-containing serum and their number estimated
with a haemocytometer. Cells were seeded at a density of 3 x 103
per 100gl ofmedium in each well ofa 96-well plate (Coming). A
single column ofeight wells from eachplate contained medium but
no cells to act as a blank control. For each experiment, five plates
were prepared such that all cells from a single plate were subjected
to the same subsequent light dose. Plates were incubated ovemight
to allow cells to stick down. The medium was removed from the
plates and the cells washed in serum-free medium. Cells from half
ofthe wells from each plate were then incubated for 4 h in serum-
free medium containing Imm ALA, while cells in the other halfof
the plate were incubated in medium alone to act as controls. An
incubation period of4 h was chosen, as in vivo studies ofthe fluo-
rescence kinetics ofALA uptake in an animal model suggest this to
be the optimum time (Loh et al, 1993). Serum-free medium was
used, because PpIX is lipophilic and quickly diffuses outofthe cell
into medium containing serum. The pH of the ALA dissolved in
medium was maintained between 7.2 and 7.6. The plates were then
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Figure 1 Fluorescence kinetics of ALA uptake in the J82 (*) and J82/MMC
(-U) cell lines. Data points represent the geometric mean of 5 x 103
observations of cellular fluorescence
After4 h ofincubation, each plate was then exposed to light from a
tungsten-halogen lamp (Micromark) for a particular time period.
Thetotal spectral irradiance atthe level ofthe cells, and in thepres-
ence ofa waterfilter, was 81 mw cm-2 (400 750nm) and measured
using an Ophir Nova power meter (Ophir Optronics) fitted with a
blackbody absorber pyroelectric head. These measurements indi-
cated that irradiance was constant over the small area occupied by
the 96-well plates. Ultraviolet light (UVA) was minimal and
measured at < 15 jw cm-2. Infrared radiation was minimized using
a 4-cm water filter between the cell plates and the light source.
Plates containing medium at 35-370C and exposed to the water-
filtered light source for 20 min did not exhibit temperature rises
exceeding 1 C.
One plate from each experiment was not exposed to light and
acted as a control. Following light exposure, all medium was
replaced with fresh serum-containing DMEM. Cell survival assays
were performed after 5 days. All photodynamic therapy experi-
ments were performed with at least 16 pairs of ALA and control
wells for each light dose for each cell line. Experiments were
performed on at least three separate occasions.
Exposure of cells to mitomycin C
Cells were plated at a cell density of3 x 103 per 100 ,ul ofmedium
in each well of a 96-well plate. Cells were incubated ovemight to
allow them to stick to the plates. Freshly prepared MMC was
dissolved in serum-supplemented medium and serial dilutions
added to the plate. Each dilution was performed eightfold,
including a single column ofeight wells with no drug added to act
as a control. One column of wells was left free ofcells to act as a
blank control. The doses ofMMC used were 0.025, 0.05, 0.1, 0.25,
0.5, 1, 2, 3, 5 and 10 gg ml-'. Preliminary experiments suggested
that short exposures to MMC (e.g. 1-4 h) were not effective at
producing more than one log of cell kill, even when very high
doses were used. Cells were therefore exposed to MMC for 24 h
before they were washed in fresh medium and incubated for a
further 5 days before assaying cell survival.
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Figure 2 Estimate of survival of the J82 (A) and J82/MMC (0) cell lines
following photodynamic therapy, using the MTT assay. Data points represent
the mean survival estimated from three separate experiments. Error bars
represent the standard error of the mean (s.e.m.). Error bars are not shown
where the s.e.m. is smaller than the symbol
Combination treatments of photodynamic therapy with MMC
were also carried out on both cell lines. For this experiment, one of
two paired plates was first exposed for 24 h to MMC, followed
24 h laterby 4 h incubation in 1 mm ALA and exposure to 10 J cm-2
photodynamic therapy. The other paired plate was exposed to
photodynamic therapy first, followed 24 h later by MMC for 24 h.
After the second treatment, cells were washed and fresh medium
added. Experiments investigating the effects ofcombined PDT and
MMC were performed simultaneously such that the time between
cell seeding and survival determination was identical (approxi-
mately 6 days). All experiments were performed in either
quadruplicate or eightfold on at least three separate occasions.
Cell survival assay
Survival assays ofthe J82 andJ82/MMC cell lines were performed
using the 'MTT' assay as previously described (Coyle et al, 1994).
After photodynamic therapy, cells were incubated in fresh medium
for 4-5 days before cell survival was determined. This meant that
the time between cell seeding and survival estimation was kept
constant for all experiments (6 days). To determine cell survival,
10 gl of 5 mg ml-' MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) (Sigma) dissolved in PBS was
added to each well. Plates were then incubated for 4 h at 37°C.
Viable cells reduce the MTT to a blue formazan dye which was
then solubilized in 100 pl per well of lysis buffer prepared from
20% sodium dodecyl sulphate (Sigma) dissolved in 50% N,N-
dimethyl formamide. Plates were incubated for a further 15-18 h
at 37°C before they were read on a computerized microplate
ELISA reader at an optical density (OD) of570 nm. The OD ofthe
blank wells were subtracted from all experimental readings and
cell survival expressed as a fraction ofOD readings ofthe control
wells. In the photodynamic therapy experiments, cell survival was
expressed as a fraction ofviable cells exposed to ALA butno light.
For both cell lines the linearity ofthe MTT assay was checked for
the seeding density and the experimental time course used, by
measuring the OD of known numbers of cells after 5-6 days of
incubation in fresh medium.
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Figure 3 Estimate of survival of the J82 (A) and J82/MMC (V) cell lines
following photodynamic therapy, using flow cytometry on a single occasion
Although the MTT assay is widely used forestimating cell death
following ALA-mediated photodynamic therapy (Riesenberg et al,
1996), this method of determining survival is not very sensitive at
high levels of cell kill. Flow cytometry, to assay cell death, was
therefore usedfollowing photodynamic therapy to bothcell lines on
a single occasion, in order to attempt discrimination between them
at high levels ofcell kill. The method used depends on the concur-
rent staining ofboth 'live' and 'dead' cells, using fluorescein diac-
etate (FDA) and propidium iodide (PI) (Ross et al, 1989).
Approximately 1 x 105 cells were counted and plated into eight 25-
cm2 flasks. Cells were incubated overnight to allow cells to stick
down. After24 h, cells were incubated for4h at37°C in serum-free
medium, with or without 1 mm ALA. Flasks were exposed to light
from the tungsten-halogen source for various times. One flask was
exposed to 70 J cm-2 of light but no ALA, whereas another was
exposed to ALA but no light. After light exposure, all medium was
changed for serum-containing medium and flasks were incubated
for a further 24 h at 37°C. Flasks were then detached by washing
twice in 0.5% trypsin-EDTA and resuspended in 5 ml of serum-
containing medium. The cells were centrifuged at 100 g for 5 min
and resuspended in 1 ml of medium. The suspensions were
prepared for the cell viability assay by adding 50 jl of 100 ,ug ml-'
propidium iodide dissolved in water (Sigma), 50 pl of 100 ng ml-
fluorescein diacetate dissolved in water (Sigma) and 15 1l of6 jim
latex beads at a concentration of 4.8 x 106 beads per ml
(Polysciences). Cells were then incubated for 10 min at room
temperature. Viable cells are able to convert the colourless fluores-
cein diacetate to fluorescent-green fluorescein. Normally, intact
membranes from viable cells are able to exclude the fluorescent-red
propidium iodide. Hence, dead cells will stain positively for this
dye. The known numberofbeads in aparticular sample allowed the
absolute number of intact cells to be estimated. Cell suspensions
were passed through aBecton-Dickinson FACScan flow cytometer.
Excitation was at 488 nm with an argon laser and emission
collected by photomultiplier tubes after passing through a 30-nm
bandpass filter centred at 530 nm for green fluorescence (viable
cells staining with fluorescein) and a 650-nm longpass filter forred
fluorescence (non-viable cells staining with propidium iodide).
Using forward- and side-scatter signals, debris was excluded from
the final data. Latex particles could be identified and counted as a
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Figure 4 Comparative survival of J82 (*) and J82/MMC (-U) cell lines
following exposure to serial dilutions of MMC. Data points represent mean
survival estimated from three separate experiments. Error bars represent the
standard error of the mean (s.e.m.). Error bars are not shown where the
s.e.m. is smaller than the symbol
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Figure 5 Effect of photodynamic therapy on survival following exposure to
serial dilutions of MMC, compared with that of MMC alone, in the J82 cell
line. Data points represent mean survival estimated from three separate
experiments. Error bars represent the standard error of the mean (s.e.m.).
Error bars are not shown where the SEM is smaller than the symbol. X,
MMC alone; - PDT followed by MMC; -_- MMC followed by PDT
1
separate population because oftheir characteristic forward and side
scatter signals and their lack offluorescence.
Data were analysed using LYSIS II software (Becton-
Dickinson) and recorded as dot-plots. A total of 10 000 events
were recorded for each cell sample. The proportion of cells
staining green compared with those staining red was recorded for
each light dose. Survival fraction was calculated as aproportion of
cells remaining intact and staining green, compared with controls
exposed to ALA but not light.
RESULTS
The ALA-induced fluorescence did not vary greatly between the
J82 and J82/MMC cell lines, during the time course of ALA
incubation used for subsequent photodynamic therapy (Figure 1).
However, after 5 h of incubation, the fluorescence of J82/MMC
cells was greater than J82 cells. In serum free medium, fluores-
cence increased approximately linearly with respect to time for up
to 24 h in both cell lines. Photodynamic therapy of the two cell
lines resulted in similar shaped light dose-dependent survival
curves (Figure 2). Following photosensitization, there is a clear
correlation between the amount of light energy delivered and the
rate ofcell kill. Increasing doses oflight without prior ALA incu-
bation had no effect on cell survival. Incubation of cells in 1 mM
ALA, but no exposure to light, likewise had no effect on cell
survival. Beyond 5 min oflight exposure, the surviving fraction of
cells was too small to be detected using the MTT assay. Both
survival curves are shouldered, which probably represents the
ability ofcells to repair photodynamic therapy-induced damage at
lower light doses. The flow cytometry method ofdetermining cell
kill, using FDA and PI stains, shows a more linear dose-response
(Figure 3). The J82/MMC cells are not cross-resistant to photo-
dynamic therapy and also appear to be more susceptible to photo-
dynamic therapy than the parent J82 cell line. This is more clearly
shown in Figure 3 when higher light doses are used and therefore
very small numbers of surviving cells are detected.
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Figure 6 Effect of photodynamic therapy on survival following exposure to
serial dilutions of MMC, compared with that of MMC alone, in the J82/MMC
cell line. Data points represent the mean survival estimated from three
separate experiments. Error bars represent the standard error of the mean
(s.e.m.). Error bars are not shown where the SEM is smaller than the symbol.
X, MMC alone; -K-, PDT followed by MMC; -_, MMC followed by PDT
Following exposure to MMC, the difference in survival between
J82 and J82/MMC cells confirms the relative resistance of the
J82/MMC line (Figure 4). Photodynamic therapy appears to
enhance the effect ofMMC on J82 cells, but only ifMMC is given
first (Figure 5). In contrast to this, photodynamic therapy appears
to enhance the effect of MMC on the J82/MMC cell line, even
when it is given first (Figure 6). This enhancement is particularly
notable in the J82/MMC cell line. Much of the difference between
the cell lines may be explained by the apparent greater sensitivity
oftheJ82/MMC cells tophotodynamic therapy. The 10 J cm-2light
dose used in the combination therapy experiment does not have an
equal effect on the two cell lines. When photodynamic therapy
alone was given, this dose oflight resulted in a survival fraction of
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approximately 65% of the J82 cells, compared with 40% of the
J82/MMC cells (Figure 2). However, in the combination therapy
experiment, there was no detectable survival when J82/MMC cells
were exposed to more than 0.05 ,ug ml-' of MMC before photo-
dynamic therapy (Figure 6). This compares with an IC90 value of
200 times this concentration when MMC was used alone.
DISCUSSION
Photodynamic therapy of cancer involves either the systemic or
topical administration of tumour-localizing photosensitizers and
their subsequent activation by light (Dougherty et al, 1988). The
presence of molecular oxygen is mandatory for the photodynamic
process to occur, as cytotoxicity and subsequent tissue destruction
requires a transfer of energy from the excited photosensitizer
molecule to singlet oxygen, followed by interaction with the
biological substrate (Moan et al, 1979; MacRobert et al, 1989).
Photodynamic therapy is usually accompanied in vivo by severe
microvascular changes (Nelson et al, 1987) associated with
endothelial damage, microcirculatory stasis, platelet aggregation
and haemorrhage, resulting in a coagulation necrosis (Bugelski et
al, 1981; Selman et al, 1984; Star et al, 1986; Chaudhuri et al,
1987). A distinct advantage ofusing ALA to generate PpIX as an
in situ photosensitizer is the relatively rapid clearance of photo-
active substances from the body. In ALA-injected mice, no tissue
exhibited more than background fluorescence 24 h after injection
(Kennedy et al, 1992).
Using confocal fluorescence microscopy, the site of PpIX
generation and photodynamic damage has been confirmed to be at
the level of the mitochondrion (Rossi et al, 1996). This contrasts
with conventional cytotoxic drugs such as MMC, which acts
following activation by the bioreductive enzymes DT diaphorase
and NADPH cytochrome P450 reductase. This results in the
formation ofhighly reactive alkylating species that produce DNA
cross-links followedby inhibition ofDNA synthesis and cell death
(Lyer et al, 1963; 1964). Another mechanism ofMMC action is by
the generation of oxyradicals such as superoxide, hydrogen
peroxide and hydroxyl groups (Bachur et al, 1978; 1979). The
complementary way in which MMC and photodynamic therapy
target different subcellular organelles suggest how the two treat-
ment modalities may be additive, but does not explain the impor-
tance of treatment sequence or the mechanism of treatment
enhancement when MMC is given first. Another possible mecha-
nism forthe enhanced effect ofthese two treatments is the factthat
the combination of photodynamic therapy induces hypoxia and
that bioreductive drugs, such as MMC, are able to particularly
target cells at low oxygen tensions (Baas et al, 1994).
The potentiation of photodynamic therapy by MMC has previ-
ously been described in human colon adenocarcinoma cells using
Photofrin as the photosensitizer (Ma et al, 1992a). By studying
cell cycle kinetics, it was established that MMC had the effect of
causing a greater proportion of cells to accumulate within the S-
phase ofthe cell cycle. The same group also showed that photody-
namic therapy decreased the proportion of cells in the S-phase of
the cell cycle and increased theGI fraction (Ma et al, 1993). This
suggests that MMC may cause accumulation of cells within that
part ofthe cell cycle (S-phase) in which they are most susceptible
to photodynamic therapy. Another possible mechanism is the
increase in cell surface area associated with photosensitizer uptake
that can occur following treatment with MMC. Observations on a
human colon adenocarcinoma cell line suggested that prior treat-
ment with MMC increased the cell surface area by 1.3- to 2.3-fold
and the uptake ofPhotofrin by 1.3- to 2.7-fold (Ma et al, 1992b).
The enhancement of photodynamic therapy by MMC has also
been demonstrated in vivo, using a mouse tumour model (Baas et
al, 1994). Using interstitial photodynamic therapy, it was shown
that prior administration ofMMC halved the light dose necessary
for a given tumour response. The same authors have also treated
four patients with breast metastases to the skin. They were able to
achieve similar responses in those tumours treated with MMC
followed by photodynamic therapy, compared with tumours
treated with photodynamic therapy alone but using twice the light
dose (Baas et al, 1996).
Although previous studies have shown that the multidrug resis-
tantphenotype does notconferresistance tophotodynamic therapy
(Lemoli et al, 1993), the effect of photodynamic therapy on
mitomycin resistance has not been reported. The kinetics ofALA-
induced fluorescence appears tobe betterin theJ82/MMC cell line
compared with the J82 cell line and may explain, at least in part,
theirdifferential photodynamic sensitivity. We are currently inves-
tigating the possible reasons for this, but hypothetical reasons for
enhanced ALA uptake and PpIX synthesis in the J82/MMC cell
line include increased mitochondrial density, increased cell
surface area or reduced ferrochelatase activity. A previous study
examining the cell cycle distribution of J82/MMC cells, showed
an increase in the proportion ofthese cells in the S-phase (Xu et al,
1994) compared with the parent line, during which they may be
more susceptible to photodynamic therapy.
The clinical implications of photodynamic susceptibility of
mitomycin resistance are important. Intravesical MMC is widely
used in the treatment of superficial bladder cancer because it is
effective and has fewer side-effects than many other cytotoxic
drugs (Harrison et al, 1983; Sommerville et al, 1985; Hetherington
et al, 1987). A scheduled course of MMC instillations following
transurethral resections of superficial bladder tumours resulted in
58% ofpatients becoming recurrence-free after 2 years, compared
with 35% receiving transurethral resection alone (Tolley et al,
1988). While these results are good, recurrences remain a problem
and potentially dangerous progression remains a risk, especially
with carcinoma in situ andTIG3 tumours. Although the true extent
of drug resistance as a mechanism of tumour recurrence is
unknown, the enhanced effect of MMC with photodynamic
therapy is apotentially exciting therapeutic strategy. It is ofpartic-
ular interest that this phenomenon appears to hold true, even in
MMC resistance. The fact that MMC resistance may enhance
photodynamic sensitivity in vitro needs further validation in vivo,
but offers the prospect of photodynamic therapy occupying an
important niche in the treatment of recurrent superficial bladder
cancer.
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